The human pathogen Leishmania donovani secretes a histidine acid phosphatase activity that is resistant to proteolytic degradation.
Promastigotes of all pathogenic Leishmania species secrete acid phosphatase (SAcP) activity during their growth in vitro. It has been suggested that this enzyme may play a role in the survival of the parasite within its sandfly-vector host. To carry out such functions, SAcP would have to be relatively resistant to endogenous sandfly gut-proteases. Therefore, the current study was undertaken to ascertain whether L. donovani SAcP activity was affected by treatment with various proteases. Native L. donovani SAcP was treated with a variety of serine-, thiol-, metallo- and mixed-proteases and subsequently assayed for enzymatic activity. Of the eleven proteases tested, only bromelain and subtilisin treatments caused a pronounced reduction in SAcP activity. Treatment of SAcP with seven out of the remaining nine proteases, resulted in an overall enhancement in SAcP enzymatic activity ranging from approximately 10% (e.g. with trypsin) to > or = 90% (e.g. with ficin). The resistance of the Leishmania SAcP to various proteases may prolong its functional life within the sandfly gut and help to facilitate parasite infection in this host.
Joshi
Manju B
MB
Cell Biology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0425, USA.
Mallinson
David J
DJ
Dwyer
Dennis M
DM
D000818:Animals; D010450:Endopeptidases / Q000378:metabolism; D006801:Humans; D006867:Hydrolases / Q000302:isolation & purification / Q000378:metabolism; D007700:Kinetics; D007893:Leishmania donovani / Q000201:enzymology* / Q000472:pathogenicity*; D013379:Substrate Specificity
D006867:Hydrolases; D010450:Endopeptidases; C400721:13 kDa phosphoamidase